Study S002177

A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06282458
Acronym: QUALITY
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 168
Start: 2024-04-29
Primary completion: 2025-04-11
Lead sponsor: Veru Inc.
Conditions: Muscle Loss; Obesity
Interventions: DRUG:Enobosarm; DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days. [Day 112]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0045473	Not All Weight Loss Is Equal: Towards Muscle‐Preserving Therapies in Obesity Joseph D Abraham, Journal of Cachexia Sarcopenia and Muscle	2026	Randomized trial	PMID 42046455 DOI	cites ClinicalTrials.gov:NCT06282458